MPAM
RLAY icon

Monarch Partners Asset Management’s Relay Therapeutics RLAY Stock Holding History

Monarch Partners Asset Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$1.27M Buy
85,139
+42,579
+100% +$815K 0.38% 121
2022
Q3 		$952K Buy
+42,560
New +$934K 0.29% 126

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Monarch Partners Asset Management's RLAY Position: Q4 2022 in Review

Monarch Partners Asset Management increased its Relay Therapeutics (RLAY) stake by 100% in Q4 2022, buying an estimated $815K and bringing the position to 85,139 shares worth $1.27M. The position accounts for 0.38% of the portfolio, ranked #121.

Monarch Partners Asset Management first reported a position in RLAY in Q3 2022 and has held it in 2 quarters since. 165 funds tracked by Wall St. Rank hold RLAY as of Q4 2022.

  • Monarch Partners Asset Management held 85,139 shares of Relay Therapeutics worth $1.27M as of Q4 2022.
  • Monarch Partners Asset Management bought 42,579 Relay Therapeutics shares in Q4 2022, an estimated $815K.
  • Relay Therapeutics made up 0.38% of Monarch Partners Asset Management's portfolio in Q4 2022, its #121 holding.
  • Monarch Partners Asset Management first reported a position in Relay Therapeutics in Q3 2022 and has held it in 2 quarters since.
  • 165 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2022.

Based on Monarch Partners Asset Management's 13F filing for Q4 2022, filed 2 Feb 2023.